Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

It will take more than waiving patent protections for coronavirus vaccines — which the Biden administration now says it supports — to fix the gaping global divide in access.

Why it matters: Waiving drug companies' intellectual property rights risks setting a bad precedent for future investment in new drugs. And that risk may not be worth it without additional steps to meaningfully increase the availability of shots across the world.

What happens next: The U.S. "will actively participate in text-based negotiations at the World Trade Organization" to waive intellectual property protections, U.S. World Trade Organization Ambassador Katherine Tai said in a statement yesterday, adding that the negotiations will take time.

If agreed to, a waiver "will create a risk-free environment for any potential manufacturers to go and reverse-engineer some of these vaccines, if they have the capability," said Tahir Amin, co-founder and co-executive director of the Initiative for Medicines, Access & Knowledge.

  • Amin said new manufacturers may be able to begin making some of the vaccines using more traditional technology by the end of the year, although it could take longer to figure out how to make mRNA vaccines.

The other side: Some experts and activists say other steps — including funding and logistical support to scale up manufacturing — would increase global vaccine supply more quickly.

  • "Unfortunately the time and energy dedicated to this negotiation may distract from and slow down what is urgently needed, which is a comprehensive approach to increasing global vaccine manufacturing capacity," said Krishna Udayakumar, director of the Duke Global Health Innovation Center.
  • "Standing up new manufacturing, even in a circumstance where you have a full tech transfer and are cooperating closely with a new manufacturing partner, which isn’t the case here, would still take six months in the best cases, and usually much longer," former FDA Commissioner Scott Gottlieb said. Gottlieb is on the board of Pfizer.

And experts are worried that weakening patent protections, in addition to being a potentially inefficient solution, would carry some significant long-term risks, especially in future pandemics.

  • "The only immediate beneficiary here is China, who has long sought a dismantling of these global rules that protect America’s intellectual property, and is positioned to copy these vaccines," Gottlieb said.
  • "I wonder whether we want to send potential firms the message that the larger the health crisis, the less we will respect and protect your IP. That's a great system if you think this is the last pandemic we'll face," tweeted Craig Garthwaite, a professor at Northwestern University.

Editors note: This story has been updated to reflect the fact that Gottlieb is on Pfizer’s board.

Go deeper

Updated Aug 16, 2021 - Health

Texas Supreme Court temporarily blocks 2 counties' mask mandates

Texas Gov. Greg Abbott (left) and Attorney General Ken Paxton. Photo: Robert Daemmrich Photography Inc./Corbis via Getty Images

The Texas Supreme Court granted an emergency stay to the state's Republican governor, Greg Abbott, over his ban on face mask mandates on Sunday.

Why it matters: The stay overrides lower court rulings in favor of local authorities in the counties of Dallas and Bexar, which includes San Antonio, to temporarily impose mask mandates despite Abbott's May executive order.

Starbucks drops worker vaccine or test requirement after SCOTUS ruling

Photo: Jakub Porzycki/NurPhoto via Getty Images

Starbucks has dropped plans to require that U.S. workers get the COVID vaccine or submit to weekly testing, the company announced Tuesday in a memo to employees.

Why it matters: The company's decision comes in response to the Supreme Court's ruling last week to block the Biden administration's COVID-19 vaccine-or-test requirement for large employers.

2 hours ago - World

Netanyahu plea talks enter crunch time

Netanyahu (right) meets with his lawyer ahead of a court hearing last February. Photo: Reuven Casto/Pool/AFP via Getty

Benjamin Netanyahu, Israel's opposition leader and former prime minister, is negotiating a possible plea deal over the corruption charges against him, but Attorney General Avichai Mandelblit appears to be toughening his terms.

Why it matters: Mandelblit leaves office on Jan. 31. Negotiations could continue beyond that point, but the next attorney general may be less interested in quickly reaching a deal.